Levosimendan for patients with severely reduced left ventricular systolic function and/or low cardiac output syndrome undergoing cardiac surgery: a systematic review and meta-analysis.

Another reason for conducting our study was the evidence in one RCT of a beneficial effect of levosimendan in the subgroup of patients with more severe reduction of LVEF (<25%) and in those undergoing isolated coronary artery bypass grafting (CABG); moreover, such RCTs showed a trend toward lower mortality at 90 days for levosimendan (4.7% vs placebo 7.1%, p = 0.12) [ 13 ].

also in 53,322 other papers